Clinical Trial Update: Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of HIP1601 in non-erosive reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-erosive Gastroesophageal Reflux Disease

Drugs mentioned

• HIP1601

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Non-erosive Gastroesphageal Reflux Disease | Phase 3 | Status: COMPLETED